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MDS % MDS/MPN % sAML % P-value
Grade 2-4 aGVHD 44 55 42 0.75
Chronic GVHD 33 35 39 0.82
5-yr Relapse Mortality 22 33 43 0.28
5-yr NRM 44 33 42 0.67
5-yr OS 34 33 15 0.82
Table 1
Baseline Characteristics of 381 patients undergoing allogeneic HSCT
Characteristic HSCT Patients (N ¼ 381)
Age (years)
Median 53
Range 19-71
Gender
Male 58.3%
Race
Caucasian 94.0%
Primary malignancy
ALL 13.1%
AML 36.0%
MDS 18.6%
CLL 11.5%
CML 6.0%
Lymphoma 4.5%
Plasma-Cell-Disorders 7.9%
Non-Malignant-Disorders 2.4%
Graft type
Peripheral-Blood 86.9%
Bone-Marrow 10.5%
Umbilical-Cord-Blood 2.6%
Total body irradiation
Myeloablative 36.0%
Reduced Intensity/Nonmyeloablative 14.4%
Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256 S227From 2000 to 2013, we retrospectively identiﬁed 142 pa-
tients who underwent HCT for MDS (n¼84), MDS/MPN
(n¼20) or secondary acute myeloid leukemia (sAML) (n¼38)
from a prior MDS or MDS/MPN, as deﬁned by WHO criteria.
Median age at transplant was 55 yrs (range 41-67) for MDS/
MPN, 52 yrs (20-70) for MDS and 56 yrs (29-73) for sAML.
Among MDS/MPN patients, 14 had CMML and 6 had MDS/
MPNunclassiﬁable, 2 of which evolved from anMPN. Prior to
HCT, 44% of MDS patients received hypomethylating agents
(HMA), 12% intensive chemotherapy (IC), and the remaining
other or no treatment. A minority received a combination of
therapy. Similarly, 40% of MDS/MPN patients received HMA,
15% IC, 20% no treatment and 30% additional treatment such
as hydrea or ruloxitinib. Most (79%) sAML patients received
IC. 36% MDS, 15% MDS/MPN and 34% sAML patients had in-
termediate or high (35%, 45%, 42%, respectively) comorbidity
scores. At time of HCT, 13% MDS, 20% MDS/MPN and 24%
sAML had >10% blasts. The majority (74% MDS, 65% MDS/
MPN, 66% sAML) received standard HCT with busulfan (Bu)/
cyclosphosphamide, and the remaining had reduced-in-
tensity HCT with ﬂudarabine (Flu)/total body irradiation or
Bu/Flu. All MDS/MPN patients had an HLAmatched related or
unrelated donor, with a minority of MDS (7%) and sAML
(16%) patients receiving cord blood.
There were no differences in time to hematopoietic recovery
or GVHD in all three disease groups. There was a higher
incidence of relapse at 5 yrs in sAML (47%) and MDS/MPN
(43%) compared to MDS (32%) however this was not signif-
icant. 100-day non-relapse mortality (NRM) was similar, 15%
MDS, 20%MDS/MPN and 13% sAML, andmost commonly due
to infection. Overall survival (OS) was worse in sAML
compared to MDS/MPN and MDS but not statistically sig-
niﬁcant (Table). Multivariable analysis identiﬁed intermedi-
ate/high risk comorbidity scores (HR 1.67, 95% CI 1.04-2.69,
p¼0.04) and blast count >10% (HR 1.69, 95% CI 1.02-2.81,
p¼0.04) as signiﬁcant risk factors for mortality. A blast count
of 5-10% (HR 1.01, 95% CI 0.6-1.7, p¼0.97) was not found to be
a signiﬁcant factor, along with diagnosis, IPSS score, cyto-
genetics, prior therapy, or conditioning regimen.
This analysis reinforces that HCT remains a valid treatment
option for patients with MDS/MPN. Relapse is still a major
cause of treatment failure and patients with high blast count
or comorbidity scores are unlikely to beneﬁt from HCT.351
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Rochester, MNBackground: Voriconazole (Vori) is a common antifungal
medication used in allogeneic hematopoietic stem cell
transplantation (allo-HSCT) patients. In solid organ trans-
plantation, multiple studies have associated the use of vori
with the development of squamous cell carcinoma (SCC)
post-transplant, but its association with SCC in allo-HSCT
patients is unknown.
Methods: Mayo Clinic’s transplant database (2007-2012)
was accessed and electronic charts of allo-HSCT patients
were reviewed. Vori exposure was deﬁned as its exposure at
any time during treatment of primary disease, prior to or
following HSCT. Cumulative vori exposure was deﬁned as
total days of voric use following HSCT; days were not
required to be consecutive. Two time-dependent vori expo-
sure variables were deﬁned: (1) history of vori exposure (yes/
no) over time, and (2) cumulative days on vori over time.
Results: 404 patients underwent allo-HSCT during this
timeframe, and 381 patients (table 1) were included in the
ﬁnal analysis. 312/381 received vori; other antifungal
therapy included ﬂuconazole (n¼40), posaconazole (n¼23),
anidulafungin (n¼1), and caspofungin (n¼5). Median
Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256S228duration of cumulative days of vori was 214 (range 2 -1553).
SCC developed in 26/312 exposed to vori and in 1/69 who
received alternative antifungals. Cumulative incidence of
SCC at 1 year was 3%, 2 years was 8%, 3 years was 13%, 4
years was 14%, and at 5 years was 19% (ﬁgure 1).
Cumulative days of vori use was found to be a risk factor
for the development of SCC, and this relationship persisted
in a multivariate model using previously identiﬁed risk
factors (gender, age at transplant, TBI , skin cancer pre-
HSCT, GVHD) as covariates (HR 1.859 for each 180 days of
use, p<0.001). History of prior vori exposure was not
associated with increased risk of SCC after covariate
adjustment (HR 2.436, p¼0.2369).
Conclusion: This is the ﬁrst study to establish cumulative
days of vori use as a risk factor for SCC development
following allo-HSCT, and may help guide appropriate anti-
fungal prophylaxis in this patient population which is
already at an increased risk of developing skin cancers.352
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Human herpesvirus 6 type B (HHV-6B) is an important
opportunistic pathogen in immunocompromised patients.
Approximately 95% of adults have evidence of past infection,
and HHV-6B reactivation occurs in approximately 30-80% of
allogeneic hematopoietic stem cell transplantation (HCT)
recipients 2-6 weeks after transplantation. HHV-6B has beenFig.1. Quantitative plasma human herpesvirus 6 (HHV-6) viral loads (VL) and liver en
phosphatase.associated with a variety of diseases that result in signiﬁcant
morbidity and mortality. We report a case of acute hepatitis
likely caused by HHV-6B in a HCT recipient who was suc-
cessfully treated with ganciclovir.
There are multiple reports of HHV-6B-associated hepatitis
following primary HHV-6 infection and liver transplantation,
but it has been well documented in only one patient after
HCT. We cared for a 23-year-old man with sickle cell disease
who underwent a matched related myeloablative HCT. His
early post-transplant course was notable for CMV reac-
tivation and gastrointestinal graft-versus-host disease for
which he completed treatment with ganciclovir and steroids,
respectively. He was admitted on D+98 for evaluation of
epigastric abdominal pain.
Initial work up was largely unremarkable, but he underwent
uncomplicated cholecystectomy on D+103 for persistent
symptoms and ultrasonographic evidence of cholelithiasis.
While recovering, new right upper quadrant tenderness, fe-
ver and transaminitis developed (Fig. 1). Extensive workup
was negative except for plasma PCR for HHV-6B DNA
(170,000 copies/mL) on D+108, and he was started on gan-
ciclovir 5 mg/kg intravenously every 12 hours. Donor and
patient testing for chromosomally integrated HHV-6 was
negative. Liver biopsy on D+113 revealed non-speciﬁc lobular
hepatitis. PCR of biopsy samples were negative for CMV, EBV,
adenovirus and HHV-7 but positive for HHV-6 (180,000
copies/reaction). Transaminases peaked at AST 719 IU/mL,
ALT 814 IU/mL and AP 378 IU/mL on D+112 and returned to
baseline on D+122. HHV-6B viral load decreased to <5,000
copies/mL by D+115. He defervesced but had mild persistent
abdominal pain at discharge. Retrospective immunohisto-
chemical stains for multiple anti-HHV-6 antibodies localized
to hepatocytes and Kupffer cells, consistent with active
infection (Fig. 2).
Determining the cause of organ dysfunction after HCT is
challenging. This is the second reported case of likely HHV-
6B-associated hepatitis following HCT, which may be an
underappreciated cause of liver disease in this population.
Prompt testing and initiation of treatment for HHV-6 afterzyme trends during hospitalization. ALT, alanine aminotransferase; AP, alkaline
